Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation ...
Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and ...
While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level ...
Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising.
Androgen deprivation is the mainstay of therapy of advanced prostate cancer treatment, but the cure rate is low and patients eventually become castrate resistant. Castration-resistant prostate ...
2024 — A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient ...
Bayer is vying for a third indication for its Nubeqa (darolutamide) in China, this time for its use in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone ...
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...
Scientists unveil the androgen clock, a precise epigenetic tool to measure long-term androgen exposure and its role in aging ...
The program includes free therapy sessions and resources for participants. "This program underscores our commitment to making high-quality mental health care accessible to those who need it most ...